Can Ustekinumab treat Crohn's disease?

Ustekinumab treats Crohn's disease, also known as Crohn's disease, an indication for which Ustekinumab is approved, and in two published trials, clinical improvement was observed using the Crohn's Disease Activity Index (CDAI), which was used to measure improvement in Crohn's disease. It looks at various signs, symptoms and other variables that have occurred over the past seven days and assigns a severity score.

Clinical remission was defined as a CDAI score reduction of ≥100 points or a CDAI score below 150 points at week 6, while clinical remission was defined as a CDAI score <150 points at week 8. By the third week, 41% to 51% experienced a CDAI score of at least 70. By week 6, this increased to 44% to 65%. 34-56% of patients achieved CDAI100 at week 6 of ustekinumab treatment, and by week 8, 21-40% of patients achieved clinical remission (CDAI150). By week 8, the response rate increased to 38-58%. At Week 44, 47% of patients treated with ustekinumab were in clinical response and off corticosteroids, compared with 30% of patients treated with placebo.

The generic drug Ustekinumab has been launched in China and is included in the medical insurance, and is only reimbursed for patients who meet the indications. The price of the 130mg/26ml intravenous injection preparation may be more than 5,000 yuan per box, and the price of the 90mg: 1.0ml*1 subcutaneous injection preparation may be more than 8,000 yuan per box. The price of the 130mg/26ml intravenous injection preparation of Ustekinumab sold overseas may be more than 2,000 US dollars per box, and the price of 45mg: 0.5ml*1 subcutaneous injection preparation per box may be more than 10,000 US dollars. There are currently no generic versions of ustekinumab produced in other overseas countries.